Display search results for ** instead (33 products)

Showing 21-30 of 33

This issue of Vital Signs, released on July 24, 2014, discusses emerging pharma trends in the Asia Pacific and how the region will act as an anchor to global pharma in coming years, especially in segments such as manufacturing, R&D and clinical trials.

USD 500.00

USD 375.00 save 25 %

11 Jul 2014  |  Global

Will Virtual CROs and Integrated Business Models Rule the Road

Insights into the innovative steps taken by CROs and pharmaceutical companies in the race for excellence and low-cost trials

This issue of Vital Signs, released on July 11, 2014, discusses game changing strategies in clinical research, including virtual clinical research organization (CRO) and the integrated business model.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on July 1, 2014, discusses the FDA approval of Biogens Eloctate, Qiagens acquisition of Primera Dx, Roches acquisition of Genia Technologies, Cues at-home connected lab test, and the Credihealth Teen Clinic.

USD 450.00

USD 337.50 save 25 %

11 Jun 2014  |  North America

Vital Signs - Value Emerging as a New Currency in Medical Imaging Markets

Value Based Imaging

The concept of value-based imaging is certainly not new, but it has garnered considerable attention from the medical imaging community over the past few years. Confined until recently to the realm of thought leaders at luminary healthcare and advocacy organizations, the concept has gained wide momentum in the past year. Since medical imaging repres...

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on June 2, 2014, discusses the latest strategy surrounding mega deals in the pharma/biotech industry, Eurofins agreement to acquire ViroCor-IBT Laboratories, Qiagens acquisition of BIOBASE, and the FDAs latest announcement on regulatory requirements for biosimilars.

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on May 1, 2014, discusses the mega deals brewing in the pharma/biotech industry, Pfizer Incs Xalkori for non-small cell lung cancer, Novartis halt on RNAi development efforts, the high-ranked Malaysian healthcare system, Roches acquisition of IQuums Liat Analyzer, and Bio-Rads acquisition of GnuBio.

USD 450.00

USD 337.50 save 25 %

Healthcare systems across the globe are facing rising operation costs, shortage of skilled labor and budgetary restraints, which has resulted in reduction in efficiency and quality of care. An increasing aging population, need for chronic disease management and providing access to healthcare for the geographically fragmented population demands the ...

USD 450.00

USD 337.50 save 25 %

06 Apr 2014  |  North America

Vital Signs - What’s New in Medical Imaging Advanced Visualization?

Evolving Customer Demands Spurring Competitive Dynamics

Ongoing technology and clinical advances in every imaging modality continue to bring advanced visualization (AV) and clinical applications to centerstage. AV is not just a core step in the interpretation workflow of each of these modalities, but essentially the set of solutions that allows to realize the promises of the advances on the equipment si...

USD 450.00

USD 337.50 save 25 %

This issue of Vital Signs, released on March 31, 2014, discusses the premium price tag of Gileads Sovaldi, Sonys genomic partnership with Illumina, and Craig Venters latest venture, Human Longevity, Inc.

USD 450.00

USD 337.50 save 25 %

In early November 2013, Frost & Sullivan conducted an online survey, followed up by a live focus group with about 20 C-suite executives from leading commercial payer organizations across the US. The goal was to gain insights into how the health insurance industry is approaching the use of analytics solutions going into 2014. Analytics solutions we...

USD 450.00

USD 337.50 save 25 %

Showing 21-30 of 33